Jubilant Pharmova Transfer Notice for Unclaimed Equity Shares

Jubilant Pharmova is notifying shareholders about the pending transfer of unclaimed equity shares to the Investor Education and Protection Fund (IEPF). This action affects shares for which dividends have remained unclaimed for seven consecutive years. Shareholders have until October 10, 2025, to claim their dividends and prevent the transfer. Unclaimed dividends will be transferred to IEPF on November 1, 2025.

Unclaimed Dividends and Share Transfer

Jubilant Pharmova is reminding shareholders about the transfer of equity shares related to unclaimed dividends to the Investor Education and Protection Fund (IEPF). This transfer is in accordance with regulations governing unclaimed dividends for seven consecutive years.

Key Dates and Actions

Shareholders who have not claimed their dividends for the financial year 2017-18 and subsequent years are urged to take immediate action. To prevent the transfer of shares to the IEPF, shareholders must claim their dividends by October 10, 2025. The actual transfer to the IEPF is scheduled for November 1, 2025.

How to Claim

To claim unclaimed dividends, shareholders should apply to Alankit Assignments Limited. Contact them at 205-208 Anarkali Complex, Jhandewalan Extension, New Delhi – 110055. It’s important to submit all necessary documents before the October 10, 2025 deadline.

Required Documents for Claim

  • Request letter duly signed by the shareholder(s).
  • Self-attested copy of PAN Card(s) of shareholder(s).
  • Photocopy of blank cancelled cheque.
  • Original Share Certificate.

If shares are transferred to IEPF, shareholders can still claim them later by applying to the IEPF Authority. If shareholders still have old share certificates, they should surrender them to claim new share certificates.

Source: BSE

InvestyWise News
InvestyWise News
Covers market-moving news with speed and precision, delivering sharp insights to help readers stay ahead in the fast-paced world of stocks.

Latest articles

Related articles

Leave a reply

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!